Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Carcinoma, Hepatocellular 37Carcinoma, Non-Small-Cell Lung 24Melanoma 19Squamous Cell Carcinoma of Head and Neck 18Colorectal Neoplasms 16Urinary Bladder Neoplasms 11Breast Neoplasms 11Lung Neoplasms 10Liver Neoplasms 10Biliary Tract Neoplasms 10Small Cell Lung Carcinoma 9Prostatic Neoplasms 9Diabetes Mellitus, Insulin-Dependent, 12 9Carcinoma, Renal Cell 9Neoplasms 8Cholangiocarcinoma 7Pancreatic Neoplasms 6Ovarian Neoplasms 6Head and Neck Neoplasms 6Adenocarcinoma Of Esophagus 6Stomach Neoplasms 5Neoplasm Metastasis 5Mesothelioma, Malignant 5Fallopian Tube Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 3Recurrence 3Mesothelioma 3Kidney Neoplasms 3Esophageal Squamous Cell Carcinoma 3

Interventions

Dexamethasone 809Bortezomib 449Lenalidomide 430Cyclophosphamide 336Melphalan 251Calcium Dobesilate 237daratumumab 218pomalidomide 202carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67isatuximab 64Prednisone 64dexamethasone 21-phosphate 63elotuzumab 60auricularum 57belantamab mafodotin 55Antilymphocyte Serum 55Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × tremelimumab × Clear all
NCT02716805 2022-10-12

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Ludwig Institute for Cancer Research

Phase 1 Terminated
6 enrolled 11 charts
Plasma cell

Diabetes Mellitus, Insulin-Dependent, 12, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡